Controlling Elevated Blood Pressure

Slides:

Advertisements

Similar presentations

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.

Advertisements

Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.

HOME AND AMBULATORY BLOOD PRESSURE MONITORING

10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.

A Controlled Trial of Renal Denervation for Resistant Hypertension

Renal denervation for resistant hypertension: it’s time to reconsider!

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.

Joint reporting from Hill Physicians and Sutter Independent Physicians 1.

Renal Sympathetic Denervation View From the EU

The Vessix Global Clinical Program REDUCE-HTN: REINFORCE

OneShot™ Renal Denervation System

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

Critical Appraisal of the Current Ongoing Study Designs

From ESH 2016 | POS 7D: Jan Rosa, MD

Renal Denervation Next Steps

Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc.

The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,

Moderate-to-Severe Asthma Management

Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.

Global SYMPLICITY Registry Locations and Inclusion Criteriaa,b.

Renal Denervation Two Late-Breaking Clinical Trials.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

A Paradigm Shift in PAH.

Pseudomonas Lung Infections in Cystic Fibrosis

Alpha-1 Antitrypsin Deficiency in COPD

The Nurse View.

Ask the Onychomycosis Expert, Part 2

The Latest Data on Oral Prostacyclin Therapy in PAH

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

This Program Will Discuss

Managing Complex Hypertension: What Every Physician Should Know

Section VIII. Ambulatory BP Measurement

Neurostimulation for the Management of Medication-Resistant Epilepsy

New Insights Into Neurogenic Orthostatic Hypotension

Resistant Hypertension

Thank you for taking the preassessment

New Treatments for CTEPH

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Resistant Hypertension: Initial Combinations of Medications

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

When Would You Use Single Inhaler Triple Therapy in COPD?

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Case Collection in RA: Highlights of an Interactive Workshop

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Examining the Latest Evidence in PAH

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Poor Response to Initial Therapy for Migraine

Controlling High Blood Pressure

The Road to Quality Improvement in HER2-Positive Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Evaluating BTK Inhibitors in CLL

A New Era of Renal Denervation Trials for Patients With Hypertension?

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Ambulatory BP Monitoring vs Office BP

Volume 377, Issue 9771, Pages (March 2011)

Clinician Referral Training

Ambulatory BP Monitoring vs Office BP

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Comparisons in CTEPH

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Improving Management of Acute HTN in Patients With Stroke

RAASi Enabling in the Modern Era

Presentation transcript:

Controlling Elevated Blood Pressure

Background

Factors for Poor Blood Pressure Control

Factors for Poor Blood Pressure Control

Strategic Approach to Treatment Adherence

Treatment Adherence Affects BP Control

Rationale for Alternative BP Control Methods

Awareness, Treatment, Control

Hypertension Treatment Options

New Guideline Recommendations for Blood Pressure Control

ESC/ESH BP Treatment Targets

What's New in the ESC/ESH Guidelines?

New Treatment Thresholds

2018 AHA Guidelines

How to Get to Treatment Goal?

Device-Based Therapy Recommendation

SYMPLICITY HTN-3

Renal Denervation

SYMPLICITY Global Registry

Understanding BP Improvements

ESH RDN Position Paper 2018

Renal Denervation for Treatment-Resistant Hypertension

Defining Resistant Hypertension

Sham-Controlled RDN Trials

SPYRAL-HTN ON-MED: Change in BP Over 6 Months

Renal Safety

FDA Approves Extension of Pivotal Studies

Conclusion

Abbreviations

Abbreviations (cont)